Keros Therapeutics (KROS) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Keros Therapeutics (KROS) has outperformed SIGA Technologies (SIGA) over the past year, losing 28.4% versus a loss of 60.4%. Over five years, SIGA leads with a -53.9% price change compared with -71.2% for KROS. SIGA Technologies is the larger company by market cap ($235.7 million vs $230.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | SIGA |
|---|---|---|
| Share price | $11.64 | $3.28 |
| Market cap | $230.79M | $235.67M |
| 1-day change | +3.84% | +0.61% |
| YTD return | -44.94% | -46.32% |
| 1-year return | -28.37% | -60.39% |
| 5-year return | -71.25% | -53.87% |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $-3.22 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $8.55 |
| 52-week low | $9.69 | $2.83 |
| Distance from 52-week high | -48.38% | -61.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +70.36% | — |
| Average volume | 196.01K | 726.75K |
| Shares outstanding | 19.83M | 71.85M |
| Employees | 92 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed SIGA by 32.0 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
KROS vs SIGA FAQ
Which is bigger, Keros Therapeutics or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $235.67M compared with $230.79M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or SIGA?
KROS returned -28.37% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.